A randomized, open‐label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis | Zendy

Cervigni Mauro | Zendy; Sommariva Monica | Zendy; Tenaglia Raffaele | Zendy; Porru Daniele | Zendy; Ostardo Edoardo | Zendy; Giammò Alessandro | Zendy; Trevisan Silvia | Zendy; Frangione Valeria | Zendy; Ciani Oriana | Zendy; Tarricone Rosanna | Zendy; Pappagallo Giovanni L. | Zendy

Premium

A randomized, open‐label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis

Author(s) -

Cervigni Mauro,

Sommariva Monica,

Tenaglia Raffaele,

Porru Daniele,

Ostardo Edoardo,

Giammò Alessandro,

Trevisan Silvia,

Frangione Valeria,

Ciani Oriana,

Tarricone Rosanna,

Pappagallo Giovanni L.

Publication year - 2017

Publication title -

neurourology and urodynamics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.918

H-Index - 90

eISSN - 1520-6777

pISSN - 0733-2467

DOI - 10.1002/nau.23091

Subject(s) - interstitial cystitis , medicine , hyaluronic acid , bladder pain syndrome , urology , chondroitin sulfate , dimethyl sulfoxide , open label , randomized controlled trial , urinary system , chemistry , organic chemistry , anatomy , glycosaminoglycan

AIMS Intravesical instillation of hyaluronic acid (HA) plus chondroitin sulfate (CS) in women with bladder pain syndrome/interstitial cystitis (BPS/IC) has shown promising results. This study compared the efficacy, safety, and costs of intravesical HA/CS (Ialuril ® , IBSA) to dimethyl sulfoxide (DMSO). METHODS Randomized, open‐label, multicenter study involving 110 women with BPS/IC. The allocation ratio (HA/CS:DMSO) was 2:1. Thirteen weekly instillations of HA (1.6%)/CS (2.0%) or 50% DMSO were given. Patients were evaluated at 3 (end‐of‐treatment) and 6 months. Primary endpoint was reduction in pain intensity at 6 months by visual analogue scale (VAS) versus baseline. Secondary efficacy measurements were quality of life and economic analyses. RESULTS A significant reduction in pain intensity was observed at 6 months in both treatment groups versus baseline ( P < 0.0001) in the intention‐to‐treat population. Treatment with HA/CS resulted in a greater reduction in pain intensity at 6 months compared with DMSO for the per‐protocol population (mean VAS reduction 44.77 ± 25.07 vs. 28.89 ± 31.14, respectively; P = 0.0186). There were no significant differences between treatment groups in secondary outcomes. At least one adverse event was reported in 14.86% and 30.56% of patients in the HA/CS and DMSO groups, respectively. There were significantly fewer treatment‐related adverse events for HA/CS versus DMSO (1.35% vs. 22.22%; P = 0.001). Considering direct healthcare costs, the incremental cost‐effectiveness ratio of HA/CS versus DMSO fell between 3735€/quality‐adjusted life years (QALY) and 8003€/QALY. CONCLUSIONS Treatment with HA/CS appears to be as effective as DMSO with a potentially more favorable safety profile. Both treatments increased health‐related quality of life, while HA/CS showed a more acceptable cost‐effectiveness profile.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research